Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.
Morningstar

Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer

Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer Platform Now Covering Majority of Patients with Solid-tumor Cancers Cofactor Genomics ...
Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
Business Wire

Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism ...